PTC Confident About Commercial Prospects For Gene Therapy Upstaza
One-Time Injection Gets CHMP Nod For AADC Deficiency
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.
